FairJourney Biologics S.A. has completed a strategic acquisition of Charles River Laboratories' South San Francisco facility, marking a significant expansion of its antibody discovery and optimization capabilities. The deal, announced on March 4, 2025, transfers ownership of all facilities, staff, and proprietary technologies to FairJourney, positioning the company as a stronger player in the antibody development landscape.
Strategic Technology Acquisition
The acquisition includes several cutting-edge platforms, notably the SuperHuman™, Cosmic™, and Tungsten™ antibody libraries, along with the sophisticated Yeast Display platform. These technologies will be integrated into FairJourney's existing portfolio, creating a more comprehensive suite of antibody discovery tools for their global customer base.
The Yeast Display method, a powerful technology for antibody engineering and optimization, will complement FairJourney's current offerings, enabling more diverse approaches to antibody development and characterization. This technological integration promises to enhance the company's ability to address complex therapeutic challenges.
Strategic Geographic Expansion
The South San Francisco location represents a strategic choice for FairJourney's expansion, as it places the company within one of the world's premier biotechnology hubs. This presence will provide direct access to a rich ecosystem of potential partners and clients, while offering localized expertise and technical support to accelerate antibody discovery programs in the region.
Enhanced Collaborative Potential
António Parada, CEO of FairJourney Biologics, emphasized the strategic importance of the acquisition: "By combining our expertise, we not only strengthen our portfolio with powerful solutions such as the SuperHuman Libraries, but also enhance our ability to deliver innovative solutions to our partners. Working together, we can push the boundaries of antibody discovery and set new industry standards."
Operational Integration
The acquisition transfers the entire South San Francisco team to FairJourney, bringing together experienced scientists and technical experts from both organizations. This integration is expected to create new opportunities for collaborative projects with leading biotech and pharmaceutical companies while advancing the company's internal research initiatives.
The combined technological and human resources will enable FairJourney to offer an expanded range of services and solutions, strengthening its position as a leader in antibody discovery and optimization. The company's enhanced capabilities will support partners throughout their drug development journey, from initial discovery to optimization and characterization.
